258 filings
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
S-8
LRMR
Larimar Therapeutics Inc
14 Mar 24
Registration of securities for employees
5:07pm
S-8
LRMR
Larimar Therapeutics Inc
14 Mar 24
Registration of securities for employees
5:07pm
10-K
2023 FY
LRMR
Larimar Therapeutics Inc
Annual report
14 Mar 24
4:25pm
8-K
LRMR
Larimar Therapeutics Inc
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
8-K
th2ofpimyn2e kfuvabl
11 Mar 24
Other Events
4:09pm
8-K
mvgbukuzg1v8930gb8er
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
ks8sllc0gkdhuppllgr
14 Feb 24
Prospectus supplement for primary offering
5:08pm
8-K
uiqu4dg m8a5
14 Feb 24
Termination of a Material Definitive Agreement
6:06am
424B5
qf7ty
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
abidxa7
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
v3hf9x3m
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
j2tw1qk8lx8uui
3 Oct 23
Departure of Directors or Certain Officers
4:31pm
8-K
ehrspt6vhhuwgr bhu
14 Aug 23
Other Events
8:00am
8-K
hfy l8if3n
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
efcm0ggmpks4sp
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
2vjin54s045y5y6ge70m
17 Jul 23
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
4:08pm
8-K
y1ivgf a1twfcqr
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm